GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » Cash Flow from Investing

Dare Bioscience (Dare Bioscience) Cash Flow from Investing : $-0.01 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Dare Bioscience spent $0.01 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Dare Bioscience spent $0.01 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Dare Bioscience Cash Flow from Investing Historical Data

The historical data trend for Dare Bioscience's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dare Bioscience Cash Flow from Investing Chart

Dare Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.14 -0.02 -0.02 -0.06 -0.63

Dare Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.01

Dare Bioscience Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Dare Bioscience's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Dare Bioscience's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dare Bioscience  (NAS:DARE) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Dare Bioscience's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.01 Mil. It means Dare Bioscience spent $0.01 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Dare Bioscience's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Dare Bioscience gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Dare Bioscience's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Dare Bioscience spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Dare Bioscience's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Dare Bioscience gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Dare Bioscience's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Dare Bioscience spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Dare Bioscience's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Dare Bioscience gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Dare Bioscience's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Dare Bioscience paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Dare Bioscience's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Dare Bioscience paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Dare Bioscience's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Dare Bioscience paid $0.00 Mil for other investing activities.


Dare Bioscience Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Dare Bioscience (Dare Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Executives
Sophia Nnenna Ononye-onyia director 1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson director, officer: Chef Executive Officer 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair officer: Chief Strategy Officer C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley director 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz director 1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman director C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert officer: Chief Financial Officer C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele director 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof officer: SVP, Chief Scientific Officer C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz officer: SVP, Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle director VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal officer: VP, General Counsel C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill officer: Principal Accounting Officer 15 GREENBRIAR CIRCLE, ANDOVER MA 01810

Dare Bioscience (Dare Bioscience) Headlines

From GuruFocus